BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting

World News: . []

CAMBRIDGE Mass April 21 2017 GLOBE NEWSWIRE -- BeiGene, Ltd NASDAQBGNE a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer today announced that pre liminar...

More news and information about BeiGene, LTD.

Published By:

Globe Newswire: 12:00 GMT Friday 21st April 2017

Published: .

Search for other references to "beigene" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers